Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Classical hematology 1

Conditions

Thrombocytopenia 4Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Solid Tumor 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Hodgkin Disease 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × romiplostim × Clear all
NCT03622931 2021-02-08

TRACEII

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 2 Terminated
21 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00413283 2013-10-24

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

Phase 2 Completed
63 enrolled 15 charts
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡